{
    "clinical_study": {
        "@rank": "75392", 
        "arm_group": [
            {
                "arm_group_label": "Low dose", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "High dose", 
                "arm_group_type": "Experimental"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of this trial is to assess and compare the\n      efficacy and safety of two dose levels of somatropin over a long period (till final height\n      is reached). This trial is an extension to trials GHRETARD/BDP/14/NL (a 2-year initial\n      trial) and GHRETARD/BPD/20/NL (a 2-year extension trial)."
        }, 
        "brief_title": "Growth Hormone Treatment of Children Diagnosed of Intrauterine Growth Retardation", 
        "completion_date": {
            "#text": "May 2005", 
            "@type": "Actual"
        }, 
        "condition": [
            "Foetal Growth Problem", 
            "Small for Gestational Age"
        ], 
        "condition_browse": {
            "mesh_term": "Fetal Growth Retardation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of the GHRETARD/BPD/20/NL trial\n\n          -  Written informed consent from child and/or parents/guardians before continuation in\n             the extension trial"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "11 Years", 
            "minimum_age": "3 Years"
        }, 
        "enrollment": {
            "#text": "75", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 28, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01697644", 
            "org_study_id": "GHRETARD/NL/21"
        }, 
        "intervention": [
            {
                "arm_group_label": "Low dose", 
                "description": "3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "High dose", 
                "description": "6 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily", 
                "intervention_name": "somatropin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Hormones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "October 2, 2012", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Rotterdam", 
                    "country": "Netherlands", 
                    "zip": "3015 GJ"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "2", 
        "official_title": "Growth Hormone Treatment of Children After Intrauterine Growth Retardation", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Christian B. Djurhuus", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Netherlands: Dutch Health Care Inspectorate", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2005", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Linear growth (height during childhood)", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Final height", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Bone maturation", 
                "safety_issue": "No"
            }, 
            {
                "measure": "Pubertal development", 
                "safety_issue": "No"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01697644"
        }, 
        "responsible_party": {
            "name_title": "Public Access to Clinical Trials", 
            "organization": "Novo Nordisk A/S"
        }, 
        "secondary_outcome": {
            "measure": "Adverse events", 
            "safety_issue": "No"
        }, 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 1990", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}